Skip to main content
. 2021 Feb 25;11(3):136. doi: 10.3390/metabo11030136

Table 1.

Biochemistry analysis of the subjects before ingestion.

Baseline Placebo
(n = 16)
SYNKEFIR™
(n = 16)
Lactate (mmol/L) 2.23 ± 0.49 2.14 ± 0.67
NH3 (μmol/L) 72 ± 32 94 ± 35
CPK (U/L) 148 ± 45 200 ± 124
Glucose (mg/dL) 91 ± 11 89 ± 9
FFA (mmol/L) 0.50 ± 0.26 0.45 ± 0.21
AST (U/L) 19 ± 4 18 ± 8
ALT (U/L) 23 ± 12 22 ± 10
TC (mg/dL) 211 ± 32 191 ± 22 *
TG (mg/dL) 81 ± 24 83 ± 26
HDL (mg/dL) 60 ± 6 57 ± 6
LDL (mg/dL) 112 ± 21 106 ± 14
BUN (mg/dL) 14.3 ± 2.9 12.9 ± 1.9
CREA (mg/dL) 1.16 ± 0.09 1.13 ± 0.11
UA (mg/dL) 5.64 ± 0.99 5.63 ± 1.17
TP (g/dL) 7.48 ± 0.43 7.36 ± 0.33
ALB (g/dL) 5.10 ± 0.33 5.11 ± 0.24

Data are shown as the mean ± SD, and intergroup differences were analyzed using Student’s unpaired t-test. * p < 0.05. NH3, blood ammonia; CK, creatine kinase; FFA, free fatty acid; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; CREA, creatine; UA, uric acid; TP, total protein; TC, total cholesterol; TG, triacylglycerol. HDL, high-density lipoprotein; LDL, low-density lipoprotein.